AbbVie Inc. $ABBV Position Increased by Apella Capital LLC

Apella Capital LLC boosted its stake in shares of AbbVie Inc. (NYSE:ABBV) by 97.9% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 20,298 shares of the company’s stock after purchasing an additional 10,041 shares during the quarter. Apella Capital LLC’s holdings in AbbVie were worth $4,230,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Thoma Capital Management LLC boosted its position in AbbVie by 13.6% during the 1st quarter. Thoma Capital Management LLC now owns 1,699 shares of the company’s stock worth $370,000 after acquiring an additional 203 shares during the period. Gilbert Capital Group Inc. increased its holdings in shares of AbbVie by 2.4% during the first quarter. Gilbert Capital Group Inc. now owns 3,917 shares of the company’s stock valued at $852,000 after purchasing an additional 93 shares during the period. Consilium Wealth Advisory LLC lifted its holdings in AbbVie by 50.4% in the first quarter. Consilium Wealth Advisory LLC now owns 3,008 shares of the company’s stock worth $654,000 after purchasing an additional 1,008 shares during the period. Focused Wealth Management Inc grew its position in AbbVie by 9.3% in the 1st quarter. Focused Wealth Management Inc now owns 9,362 shares of the company’s stock valued at $2,036,000 after buying an additional 793 shares in the last quarter. Finally, Centennial Wealth Advisory LLC grew its position in AbbVie by 6.5% in the 1st quarter. Centennial Wealth Advisory LLC now owns 2,254 shares of the company’s stock valued at $491,000 after buying an additional 137 shares in the last quarter. 70.23% of the stock is currently owned by institutional investors.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Canaccord raised its price target on AbbVie to $273 from $265 and reiterated a Buy rating, saying the Apogee acquisition improves AbbVie’s long-term growth outlook. Canaccord Says AbbVie’s (ABBV) Apogee Deal Strengthens Long-Term Growth Outlook
• Positive Sentiment: AbbVie’s Apogee deal is being viewed as a potentially accretive immunology bet, with articles highlighting the chance to add a prospective blockbuster asset and boost future revenue growth. AbbVie Just Sparked a 46% Rally in Apogee. Here’s Why This $10.9 Billion Deal Could Be a Win for AbbVie Investors.
• Positive Sentiment: AbbVie also expanded its pipeline by launching a new Phase 1 safety study for bretisilocin, adding another early-stage growth opportunity. AbbVie Expands Pipeline With New Bretisilocin Phase 1 Safety Study
• Positive Sentiment: AbbVie received EU approval for Skyrizi in pediatric plaque psoriasis, expanding the drug’s addressable market and supporting its immunology franchise. AbbVie Gets EU Nod for Skyrizi in Pediatric Plaque Psoriasis
• Neutral Sentiment: Several lifestyle and brand-related items highlighted Allergan Aesthetics and BOTOX® Cosmetic initiatives, including Formula Wellness earning Top 50 status and the Confidence Collective entrepreneur program. These reinforce AbbVie’s consumer aesthetics presence, but are unlikely to move the stock materially on their own. Formula Wellness Earns Top 50 Status for 2026 from Allergan Aesthetics

AbbVie Stock Performance

Shares of NYSE:ABBV opened at $243.65 on Friday. The stock has a market capitalization of $430.47 billion, a price-to-earnings ratio of 120.02, a PEG ratio of 0.72 and a beta of 0.32. AbbVie Inc. has a 1-year low of $181.73 and a 1-year high of $244.81. The company has a 50 day moving average price of $214.30 and a 200 day moving average price of $218.96.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, beating analysts’ consensus estimates of $2.59 by $0.06. The company had revenue of $15 billion during the quarter, compared to the consensus estimate of $14.72 billion. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The company’s quarterly revenue was up 12.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.46 EPS. On average, sell-side analysts expect that AbbVie Inc. will post 14.29 EPS for the current fiscal year.

AbbVie Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 2.8%. The ex-dividend date of this dividend is Wednesday, July 15th. AbbVie’s dividend payout ratio is currently 340.89%.

Wall Street Analyst Weigh In

ABBV has been the topic of a number of recent analyst reports. DZ Bank upgraded shares of AbbVie from a “hold” rating to a “strong-buy” rating in a research report on Thursday, April 30th. Bank of America upgraded shares of AbbVie from a “neutral” rating to a “buy” rating and set a $234.00 price objective on the stock in a research note on Thursday, April 30th. BMO Capital Markets reissued an “outperform” rating on shares of AbbVie in a report on Monday, March 9th. Morgan Stanley upped their target price on AbbVie from $270.00 to $278.00 and gave the stock an “overweight” rating in a research report on Thursday, April 30th. Finally, William Blair reaffirmed an “outperform” rating on shares of AbbVie in a research note on Monday, March 9th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat, AbbVie presently has a consensus rating of “Moderate Buy” and a consensus price target of $253.81.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.